Table 3.
Efficacy data of the overall population based on standard/modified FIrB/FOx regimens K/NRAS mutational status
| Overall | Standard FIrB/FOx | Modified FIrB/FOx | K/NRAS, BRAF wild type | K/NRAS mutant | |
|---|---|---|---|---|---|
|
| |||||
| Enrolled patients | 85 | 58 | 27 | 21 | 53 |
| Median PFS (months) | 14.4 | 14.4 | 14.4 | 15.3 | 14.4 |
| 95% CI | 13.2–16.5 | 13.2–16.5 | 10.9–18.7 | 13.9–17.7 | 12.8–20.2 |
| Progression events | 72 | 50 | 22 | 17 | 45 |
| P-value | – | P=0.8589 | P=0.8753 | ||
| Median OS (months) | 34.9 | 37.8 | 26.6 | 37.8 | 51.4 |
| 95% CI | 26.3–47.6 | 28.2–54.1 | 23.8–46.6 | 28.2–46.6 | 26.1–59.0 |
| Deaths | 52 | 37 | 15 | 15 | 28 |
| P-value | – | P=0.7746 | P=0.8527 | ||
Abbreviations: PFS, progression-free survival; OS, overall survival.